Business
Avidity Biosciences to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020
LA JOLLA, Calif., Nov. 5, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"LA JOLLA, Calif., Nov. 5, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Sarah Boyce, President and Chief Executive Officer, will be presenting at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020 on Thursday, November 12th, 2020 at 8:45am PST. The conference is being held in a virtual format.\n\n \n \n \n \n \n \n\n \nA live webcast of the virtual fireside chat will be available on the Company's website at www.aviditybiosciences.com in the Investor Resources section. A replay of the fireside presentation will be archived on the site for one year.\nAbout Avidity BiosciencesAvidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead \nproduct candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has research efforts focused on immune and other cell types.\nAvidity is headquartered in La Jolla, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn.\nContacts:\nCompany:\nMike MacLean(858) [email protected] \nMedia and Investors:\nAmy ConradJuniper Point(858) [email protected]\n\n\n\n View original content to download multimedia:http://www.prnewswire.com/news-releases/avidity-biosciences-to-present-at-the-credit-suisse-29th-annual-virtual-healthcare-conference-2020-301167367.html\nSOURCE Avidity Biosciences, Inc.","length":4477,"tagName":"div"}]